**Table of Contents – mapping [INSERT COMPANY NAME] TOC to TransCelerate CPT TOC**

Versions Compared: **[INSERT COMPANY NAME] [DATE]** TransCelerate May 2017.

| 1. TransCelerate CPT  Heading | 1. Section IN toc | | 1. Comments/GAPS |
| --- | --- | --- | --- |
| 1. TransCeleratE CPT SECTION # | 1. [Company NAME]   **SECTION #** |
| 1. Title Page | 1. NONE |  |  |
| 1. Signature Page | 1. NONE |  |  |
| 1. Protocol Amendment Summary of Changes Table | 1. NONE |  |  |
| 1. Table of Contents | 1. none |  |  |
| 1. Protocol Summary | 1. 1. |  |  |
| 1. Synopsis | 1. 1.1. |  |  |
| 1. Schema | 1. 1.2. |  |  |
| 1. Schedule of Activities(SoA) | 1. 1.3. |  |  |
| 1. Introduction | 1. 2. |  |  |
| 1. Study Rationale | 1. 2.1. |  |  |
| 1. Background | 1. 2.2. |  |  |
| 1. Benefit/Risk Assessment | 1. 2.3. |  |  |
| Objectives and Endpoints | 1. 3. |  |  |
| 1. Study Design | 1. 4. |  |  |
| 1. Overall Design | 1. 4.1. |  |  |
| 1. Scientific Rationale for Study Design | 1. 4.2. |  |  |
| 1. Justification for Dose | 1. 4.3. |  |  |
| End of Study Definition | 1. 4.4. |  |  |
| 1. Study Population | 1. 5. |  |  |
| 1. Inclusion Criteria | 1. 5.1. |  |  |
| 1. Exclusion Criteria | 1. 5.2. |  |  |
| 1. Lifestyle Considerations | 1. 5.3. |  |  |
| 1. Meals and Dietary Restrictions | 1. 5.3.1. |  |  |
| 1. Caffeine, Alcohol, and Tobacco | 1. 5.3.2. |  |  |
| 1. Screen Failures | 1. 5.4. |  |  |
| 1. Study Intervention | 1. 6. |  |  |
| 1. Study Intervention(s) Administered | 1. 6.1. |  |  |
| 1. Medical Devices | 1. 6.1.1. |  |  |
| 1. Preparation/Handling/Storage/ Accountablility | 1. 6.2. |  |  |
| 1. Measures to Minimize Bias: Randomization and Blinding | 1. 6.3. |  |  |
| 1. Study Intervention Compliance | 1. 6.4. |  |  |
| 1. Concomitant Therapy | 1. 6.5. |  |  |
| 1. Rescue Medicine | 1. 6.5.1. |  |  |
| 1. Dose Modification | 1. 6.6. |  |  |
| 1. Intervention after the End of the Study | 1. 6.7. |  |  |
| 1. Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal | 1. 7. |  |  |
| 1. Discontinuation of Study Intervention | 1. 7.1. |  |  |
| 1. Temporary Discontinuation | 1. 7.1.1. |  |  |
| 1. Rechallenge | 1. 7.1.2. |  |  |
| 1. Participant Discontinuation/Withdrawal from the Study | 1. 7.2. |  |  |
| 1. Lost to Follow Up | 1. 7.3. |  |  |
| 1. Study Assessments and Procedures | 1. 8. |  |  |
| 1. Efficacy Assessments | 1. 8.1. |  |  |
| 1. Safety Assessments | 1. 8.2. |  |  |
| 1. Physical Examinations | 1. 8.2.1. |  |  |
| 1. Vital Signs | 1. 8.2.2. |  |  |
| 1. Electrocardiograms | 1. 8.2.3. |  |  |
| 1. Clinical Safety Laboratory Assessments | 1. 8.2.4. |  |  |
| 1. Suicidal Risk Monitoring | 1. 8.2.5. |  |  |
| 1. Adverse Events and Serious Adverse Events | 1. 8.3. |  |  |
| 1. Time Period and Frequency for Collecting AE and SAE Information | 1. 8.3.1. |  |  |
| 1. Method of Detecting AEs and SAEs | 1. 8.3.2. |  |  |
| 1. Follow-up of AEs and SAEs | 1. 8.3.3. |  |  |
| 1. Regulatory Reporting Requirements for SAEs | 1. 8.3.4. |  |  |
| 1. Pregnancy | 1. 8.3.5. |  |  |
| 1. Cardiovascular and Death Events | 1. 8.3.6. |  |  |
| 1. Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs or SAEs | 1. 8.3.7. |  |  |
| 1. Medical Device Incidents (Including Malfunctions) | 1. 8.3.8. |  |  |
| 1. Treatment of Overdose | 1. 8.4. |  |  |
| 1. Pharmacokinetics | 1. 8.5. |  |  |
| 1. Pharmacodynamics | 1. 8.6. |  |  |
| 1. [Genetics] | 1. 8.7. |  |  |
| 1. Biomarkers | 1. 8.8. |  |  |
| 1. Immunogenicity Assessments [if applicable] | 1. 8.8.1. |  |  |
| 1. RNA Transcriptome Research [if applicable] | 1. 8.8.2. |  |  |
| 1. RNA Expression Research of a Subset of RNA Species[if applicable] | 1. 8.8.3. |  |  |
| 1. Proteome Research [if applicable] | 8.8.4. |  |  |
| 1. Metabolomic Research [if applicable] | 1. 8.8.5. |  |  |
| 1. [Health Economics] OR [Medical Resource Utilization and Health Economics] | 1. 8.9. |  |  |
| 1. Statistical Considerations | 9. |  |  |
| Statistical Hypotheses | 1. 9.1. |  |  |
| Sample Size Determination | 1. 9.2. |  |  |
| 1. Populations for Analyses | 1. 9.3. |  |  |
| 1. Statistical Analyses | 1. 9.4. |  |  |
| 1. Efficacy Analyses | 1. 9.4.1. |  |  |
| 1. Safety Analyses | 1. 9.4.2. |  |  |
| 1. Other Analyses | 1. 9.4.3. |  |  |
| 1. Interim Analyses | 1. 9.5. |  |  |
| 1. Data Monitoring Committee (DMC) | 1. 9.5.1. |  |  |
| 1. Supporting Documentation and Operational Considerations | 1. 10. |  |  |
| 1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations | 1. 10.1. |  |  |
| 1. Regulatory and Ethical Considerations | 1. 10.1.1. |  |  |
| 1. Financial Disclosure | 1. 10.1.2. |  |  |
| 1. Informed Consent Process | 1. 10.1.3. |  |  |
| 1. Data Protection | 1. 10.1.4. |  |  |
| 1. Committee Structure | 1. 10.1.5. |  |  |
| 1. Dissemination of Clinical Study Data | 1. 10.1.6. |  |  |
| 1. Data Quality Assurance | 1. 10.1.7. |  |  |
| 1. Source Documents | 1. 10.1.8. |  |  |
| 1. Study and Site Closure | 1. 10.1.9. |  |  |
| 1. Publication Policy | 1. 10.1.10. |  |  |
| 1. Appendix 2: Clinical Laboratory Tests | 1. 10.2. |  |  |
| 1. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow up, and Reporting | 1. 10.3. |  |  |
| 1. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information | 1. 10.4. |  |  |
| 1. Appendix 5: Genetics | 1. 10.5. |  |  |
| 1. Appendix 6: Liver Safety: Suggested Actions and Follow up Assessments [and Study Intervention Rechallenge Guidelines] | 1. 10.6. |  |  |
| 1. Appendix 7: Medical Device Incidents: Definition and Procedures for Recording, Evaluating, Follow up, and Reporting | 1. 10.7. |  |  |
| 1. Appendix 8:Country-specific Requirements | 1. 10.8. |  |  |
| 1. Appendix 9: Abbreviations | 1. 10.9. |  |  |
| 1. Appendix 10: Protocol Amendment History | 1. 10.10. |  |  |
| 1. References | 1. 11. |  |  |